Biologics for Chronic Spontaneous Urticaria: Complete Treatment Guide

Chronic spontaneous urticaria (CSU) is defined as hives lasting more than six weeks without an identifiable trigger. Biologics, specifically omalizumab, represent third-line therapy for refractory CSU.

When Biologics Are Considered

• Severe symptoms impairing quality of life (sleep, work, mental health)
• Inadequate response to high-dose second-generation H1-antihistamines (up to 4× standard dose)
• Intolerance or contraindications to cyclosporine or other immunosuppressants
• Need for long-term control without steroid dependence

Omalizumab (Anti-IgE)

• FDA-approved for CSU in patients ≥12 years
• 300 mg subcutaneous injection every 4 weeks
• Response typically within 1–2 doses; trial period of 3–6 months
• Favorable safety profile; no routine lab monitoring required

Key Considerations

• Cost: High; prior authorization needed; assistance programs available.
• Duration: Often continued 6–24 months; reassess for remission off therapy.
• Alternatives: Cyclosporine, dupilumab (emerging evidence), JAK inhibitors (investigational).

Treatment decisions should be individualized with an allergist/immunologist or dermatologist experienced in CSU management.